지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
The World Health Organization (WHO) declared the outbreak of H1N1 pandemic in 2009. South Korea also had outbreaks of H1N1 virus and used oseltamivir in large volume with increased reports of adverse drug reaction(ADR). The present study was aimed to investigate the ADR frequency, the factors related to ADR, and characteristics of oseltamivir's ADR. Participants for the study were patients randomly drawn from those who were prescribed oseltamivir for treatment from CHA Bundang Medical Center during October 1 and October 30. The information examined as factors related to ADR were collected by a subsequent cross-sectional telephone survey. The factors are the following; a) age;b) gender; c) patient medical history; d) diagnosis of H1N1 virus; e) adherence; f) whether taking other medication with oseltamivir or not; and g) the number of combined medications. We also asked ADR after taking oseltamivir. Total subjects were 86 patients. The average age is 22.6±18.48 years old. The gender was 45.3% women and 54.7% men. Half (50%) of all respondents showed one or more ADR, 67.4% were positively diagnosed for H1N1 virus, and 54.7% were completed the full course of oseltamivir (i.e. twice daily x 5days). The most frequently reported ADR symptoms were:dizziness (15.1%), nausea (11.6%), lethargy (10.4%), diarrhea (10.4%), abdominal pain (8.1%), headache and vomiting (6.9%). ADR classifications by categories are gastro intestinal (44.2%), neuropsychiatric events (22.1%), systemic symptom (20.9%), skin events (5.8%), eye events (4.7%), and other cases (2.3%). The onset of ADR 'after taking 1~3doses' was 69.7%. No increase in neuropsychiatric events was detected in children and adolescents. No factors examined for the study do have significant influence on the presence of ADR. This study showed that ADR of oseltamivir have occurred in half of the patients. The use of oseltamivir is essential for treatment and prophylaxis of influenza A(H1N1). But mass treatment should be properly monitored for ADR.
목차
등록된 정보가 없습니다.
참고문헌 (32)
참고문헌 신청
/ / Roche Products Limited. Summary of product characteristics for Tamiflu. The electronic Medicines Compendium (eMC). Hertfordshire: 2009
CDC / / Interim guidance on antiviral recommendations for patients with confirmed or suspected swine influenza A(H1N1) virus infection and close contact, 2009
Edwards IR / 2000 / Adverse drug reactions: definitions, diagnosis, and management / Lancet 356 : 1255 ~ 1259
FDA / / The definition of ADR
Gillissen A / 2002 / Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment / Med Microbial Immunol 191 (3) : 165 ~ 168
CDC / / Interim guidance on antiviral recommendations for patients with confirmed or suspected swine influenza A(H1N1) virus infection and close contact, 2009
Edwards IR / 2000 / Adverse drug reactions: definitions, diagnosis, and management / Lancet 356 : 1255 ~ 1259
FDA / / The definition of ADR
Gillissen A / 2002 / Early therapy with the neuraminidase inhibitor oseltamivir maximizes its efficacy in influenza treatment / Med Microbial Immunol 191 (3) : 165 ~ 168
이 논문의 저자 정보
최근 본 자료
댓글(0)
0